Interestingly, NT-0249, a brain-penetrant NLRP3 inhibitor, induced weight loss in obese mice comparable to that caused by semaglutide, an anti-diabetic drug that is also used to treat obesity (Thornton et al., 2024). Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.